Mario Alberto Isiordia-Espinoza1, Othoniel H Aragon-Martinez2, Ronell E Bollogna-Molina3, Ángel J Alonso-Castro4. 1. 1Departamento de Investigación, Escuela de Odontología, Universidad Cuauhtémoc plantel San Luis, Av. Dr. Salvador Nava Martínez # 3291, Col., Viveros, C.P. 78290 San Luis Potosí, Mexico. 2. 2Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico. 3. 3Departamento de Investigación, Facultad de Odontología, Universidad de la República (UDELAR), Montevideo, Uruguay. 4. 4División de Ciencias Naturales y Exactas, Departamento de Farmacia, Universidad de Guanajuato, Guanajuato, Mexico.
Abstract
PURPOSE: The aim of this systematic review and meta-analysis was to evaluate the risk of surgical infection, alveolar osteitis, and adverse effects using systemic metronidazole in comparison with placebo in healthy patients undergoing third molar surgery. MATERIALS AND METHODS: The eligible reports were identified from diverse science sources. Clinical trials meeting the inclusion and exclusion criteria and an acceptable Oxford Quality Score were included in this study. The evaluation of risk was done using the Risk Reduction Calculator and Review Manager 5.3., from the Cochrane Library. A significant risk reduction was assumed when the upper limit of the 95% confidence intervals was <1 and the lower limit did not cross zero (negative number) alongside a p value of <0.05 for the overall test. Data of 667 patients from five clinical trials were used for the assessment of risk. RESULTS: Our analysis showed no reduction of the risk of infection or dry socket in patients receiving metronidazole compared to whom took placebo. Meanwhile, the adverse effects did not exhibit a difference between the studied groups. CONCLUSION: The routine use of systemic metronidazole to prevent surgical site infection and/or dry socket in healthy patients undergoing third molar surgery is not recommended.
PURPOSE: The aim of this systematic review and meta-analysis was to evaluate the risk of surgical infection, alveolar osteitis, and adverse effects using systemic metronidazole in comparison with placebo in healthy patients undergoing third molar surgery. MATERIALS AND METHODS: The eligible reports were identified from diverse science sources. Clinical trials meeting the inclusion and exclusion criteria and an acceptable Oxford Quality Score were included in this study. The evaluation of risk was done using the Risk Reduction Calculator and Review Manager 5.3., from the Cochrane Library. A significant risk reduction was assumed when the upper limit of the 95% confidence intervals was <1 and the lower limit did not cross zero (negative number) alongside a p value of <0.05 for the overall test. Data of 667 patients from five clinical trials were used for the assessment of risk. RESULTS: Our analysis showed no reduction of the risk of infection or dry socket in patients receiving metronidazole compared to whom took placebo. Meanwhile, the adverse effects did not exhibit a difference between the studied groups. CONCLUSION: The routine use of systemic metronidazole to prevent surgical site infection and/or dry socket in healthy patients undergoing third molar surgery is not recommended.
Entities:
Keywords:
Adverse effects; Alveolar osteitis; Metronidazole; Surgical infection; Third molar surgery
Authors: M A Isiordia-Espinoza; O H Aragon-Martinez; J F Martínez-Morales; J R Zapata-Morales Journal: Br J Oral Maxillofac Surg Date: 2015-08-25 Impact factor: 1.651
Authors: J M Lacasa; J A Jiménez; V Ferrás; M Bossom; O Sóla-Morales; C García-Rey; L Aguilar; J Garau Journal: Int J Oral Maxillofac Surg Date: 2007-01-16 Impact factor: 2.789
Authors: Giovanni Lodi; Lara Figini; Andrea Sardella; Antonio Carrassi; Massimo Del Fabbro; Susan Furness Journal: Cochrane Database Syst Rev Date: 2012-11-14
Authors: Giovanni Lodi; Lorenzo Azzi; Elena Maria Varoni; Monica Pentenero; Massimo Del Fabbro; Antonio Carrassi; Andrea Sardella; Maddalena Manfredi Journal: Cochrane Database Syst Rev Date: 2021-02-24
Authors: Lorenzo Franco-de la Torre; Norma Patricia Figueroa-Fernández; Diana Laura Franco-González; Ángel Josabad Alonso-Castro; Federico Rivera-Luna; Mario Alberto Isiordia-Espinoza Journal: Pharmaceuticals (Basel) Date: 2021-04-14
Authors: Giath Gazal; Khalid H Al-Samadani; Hamdi Mohammed Alsaidalani; Ghofran Ali Karbouji; Abdullah Mohammed Alharbi Journal: Int J Environ Res Public Health Date: 2022-03-31 Impact factor: 3.390